Clinical Trial Update: An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease [Phase 3]

View source ↗

Summary

Pfizer conducted an extension to a Phase 3 protocol to evaluate the long-term safety and tolerability of dimebon (latrepirdine) in Alzheimer’s disease, and the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2012-11-14